SCHEMBL3589944

SCHEMBL3589944

CCOC(=O)c1cc(C#N)c(Cl)nc1C(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 13/20 0.53
HSD17B10 Q99714 3/20 0.53
L3MBTL1 Q9Y468 7/20 0.51
GAA P10253 1/20 0.51
ALDH1A1 P00352 11/20 0.50
KMT2A Q03164 5/20 0.50
MAPT P10636 4/20 0.50
MEN1 O00255 4/20 0.50
RXFP1 Q9HBX9 1/20 0.50
TDP1 Q9NUW8 4/20 0.45
NPSR1 Q6W5P4 5/20 0.44
GPR55 Q9Y2T6 2/20 0.44
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
LMNA P02545 2/20 0.43
HPGD P15428 2/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3591506 0.93 KDM4E (0.53) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL4112789 0.89 KDM4E (0.54) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL19601383 0.86 KDM4E (0.54) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL20829175 0.85 L3MBTL1 (0.54) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL4874531 0.84 KDM4E (0.60) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL3594281 0.83 CYP4F2 (0.43) KDM4EHSD17B10ALDH1A1MAPTTDP1
SCHEMBL3227432 0.83 KDM4E (0.71) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL29795714 0.82 KDM4E (0.50) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL3581480 0.81 KDM4E (0.54) KDM4EHSD17B10L3MBTL1GAAALDH1A1
SCHEMBL4109638 0.81 L3MBTL1 (0.57) KDM4EHSD17B10L3MBTL1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12508268-B2 Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2025-12-30 US disclosed
US-20240285641-A1 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2024-08-29 US disclosed
CN-117618423-A Inhibitors of tryptophan dioxygenase (IDO 1 and TDO) and their use in therapy 奥克兰联合服务有限公司 2024-03-01 CN disclosed
CN-117599049-A Inhibitors of tryptophan dioxygenase (IDO 1 and TDO) and their use in therapy 奥克兰联合服务有限公司 2024-02-27 CN disclosed
US-11826316-B2 Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2023-11-28 US disclosed
EP-3180002-B1 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LTD (NZ) 2022-04-20 EP disclosed
US-11178872-B2 Cyclic amine compound and pest control agent NIPPON SODA CO., LTD. (JP) 2021-11-23 US disclosed
US-11178872-B2 Cyclic amine compound and pest control agent NIPPON SODA CO., LTD. (JP) 2021-11-23 US disclosed
EP-3889137-A1 CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT Nippon Soda Co., Ltd. (JP) 2021-10-06 EP disclosed
US-20210145839-A1 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2021-05-20 US disclosed
US-20170224701-A1 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2017-08-10 US disclosed
EP-3180002-A1 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY Auckland Uniservices Limited (NZ) 2017-06-21 EP disclosed
WO-2016024233-A1 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 AND TDO) AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2016-02-18 WO disclosed
US-20100069350-A1 New Pyridine Analogues III ASTRAZENECA AB (SE) 2010-03-18 US disclosed
EP-2044050-A1 NEW PYRIDINE ANALOGUES Astra Zeneca AB (SE) 2009-04-08 EP disclosed
US-20080312208-A1 Pyridine Analogues ASTRAZENECA AB (SE) 2008-12-18 US disclosed
EP-1904474-A1 NEW PYRIDINE ANALOGUES AstraZeneca AB (SE) 2008-04-02 EP disclosed
US-20080039437-A1 New Pyridine Analogues III ASTRAZENECA AB (SE) 2008-02-14 US disclosed
WO-2008004946-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2008-01-10 WO disclosed
WO-2007008140-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11826316-B2 Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy IDO1, TDO2, IDO2 KDM4E 768/4885HSD17B10 1530/4885L3MBTL1 3355/4885
US-20240285641-A1 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY IDO1, TDO2, IDO2 KDM4E 768/4885HSD17B10 1530/4885L3MBTL1 3355/4885
US-12508268-B2 Inhibitors of tryptophan dioxygenases (IDO1 and TDO) and their use in therapy IDO1, IDO2, TDO2 KDM4E 1473/4885HSD17B10 1489/4885L3MBTL1 3879/4885
US-20080039437-A1 New Pyridine Analogues III P2RY12, P2RY1, P2RY11 KDM4E 2658/4885HSD17B10 4115/4885L3MBTL1 4870/4885
US-20170224701-A1 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY IDO1, TDO2, IDO2 KDM4E 768/4885HSD17B10 1530/4885L3MBTL1 3355/4885
US-20100069350-A1 New Pyridine Analogues III P2RY12, P2RY11, P2RY1 KDM4E 3901/4885HSD17B10 3604/4885L3MBTL1 4818/4885
US-20080312208-A1 Pyridine Analogues P2RY12, P2RY11, P2RY1 KDM4E 1759/4885HSD17B10 3283/4885L3MBTL1 4857/4885
US-20210145839-A1 INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY IDO1, TDO2, IDO2 KDM4E 768/4885HSD17B10 1530/4885L3MBTL1 3355/4885
US-11178872-B2 Cyclic amine compound and pest control agent H1-4, H1-10, NPR1 KDM4E 587/4885HSD17B10 3853/4885L3MBTL1 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.